Psma-targeted radiopharmaceuticals for treatment of cancer

CR20260079APending Publication Date: 2026-05-20FUSION PHARMA INC

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: CR · CR
Patent Type: Applications
Current Assignee / Owner: FUSION PHARMA INC
Filing Date: 2024-07-26
Publication Date: 2026-05-20

Application Information

Patent Timeline

26 Jul 2024

Application

20 May 2026

Publication

CR20260079A

IPC: C07K5/037; A61K47/12; A61K47/18; A61K47/22; A61K51/08; A61P35/00

CPC: A61K47/12; A61K47/22; A61P35/00; C07K5/0215; A61K47/183; A61K47/186; A61K9/0019; A61K51/0497

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

Patent Text Reader

Abstract

Pharmaceutical compositions comprising radioconjugate 225 This document discloses the formulation I and methods of its use for the treatment of PSMA-expressing cancer. Methods for preparing these pharmaceutical compositions are also disclosed herein.

Need to check novelty before this filing date? Find Prior Art